Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · IEX Real-Time Price · USD
16.50
+0.14 (0.86%)
At close: Jul 19, 2024, 4:30 PM
16.49
-0.01 (-0.06%)
Pre-market: Jul 20, 2024, 9:25 AM EDT
Company Description
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Tectonic Therapeutic, Inc.
| Country | MA |
| Founded | 2019 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Dr. Alise S. Reicin M.D., Ph.D. |
Contact Details
Address: 490 Arsenal Way, Suite 210 Watertown, Massachusetts 02472 United States | |
| Phone | (339) 666-3320 |
Stock Details
| Ticker Symbol | TECX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681087 |
| ISIN Number | US8789721086 |
| Employer ID | 81-0710585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Erik John Ostrowski M.B.A. | President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer |
| Dr. Azadeh Golipour Ph.D. | Chief Technology Officer |
| Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer |
| Jeffrey Medin Ph.D. | Scientific Founder |
| Steven N. Avruch J.D. | Chief Legal Officer and Secretary |
| Scott Gottesman | Vice President of Human Resource |
| Kirsten Dupuis | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 5, 2024 | 8-K | Current Report |
| Jul 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 27, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 26, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K/A | [Amend] Current report |